Weekly Intelligence · 6 articles

Vet Industry Intel: Feb 22 – Feb 28, 2026

High-signal veterinary industry stories triangulated from multiple sources, scored for relevance, and grouped by event type.

Acquisitions & M&A (1) Regulatory & Policy (2) Products & Technology (3)

Acquisitions & M&A

Feb 23, 2026 [10/10] gnews_practice_merger

Covetrus and MWI Animal Health agree to merge in $3.5 billion deal - DVM360

Covetrus and MWI Animal Health have agreed to merge in a $3.5 billion deal, as reported by DVM360.

Covetrus · MWI Animal Health · DVM360

Regulatory & Policy

Feb 26, 2026 [8/10] fda_cvm

FDA approves first and only second-generation Janus kinase inhibitor - DVM360

The FDA has approved the first and only second-generation Janus kinase inhibitor for veterinary use, according to reports by DVM360.

FDA · DVM360

Feb 23, 2026 [8/10] fda_cvm

FDA issues Emergency Use Authorizations for NWS meds for dogs, cats - Veterinary Practice News

The FDA has issued Emergency Use Authorizations for New World Screwworm (NWS) medications for dogs and cats.

FDA · Veterinary Practice News

Products & Technology

Feb 27, 2026 [8/10] fda_cvm

Wrap up: Merck Animal Health’s atinvicitinib tablets receive FDA approval, and other news - DVM360

Merck Animal Health received FDA approval for its atinvicitinib tablets, as highlighted in veterinary industry news.

Merck Animal Health · FDA · DVM360

Feb 26, 2026 [8/10] fda_cvm

FDA Approves NUMELVI from Merck Animal Health for the Control of Pruritus in Dogs - Pet Age

The FDA approved NUMELVI from Merck Animal Health for the control of pruritus in dogs.

Merck Animal Health · FDA · Pet Age

Feb 27, 2026 [7/10] fda_cvm

Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics - PR Newswire

Gallant has partnered with MWI Animal Health to distribute its anticipated FDA-conditionally approved stem cell therapy directly to veterinary clinics.

Gallant · MWI Animal Health